|
Daiichi Sankyo Adopts Genedata Biologics to Automate the Discovery of Novel Biological Therapeutics
Wednesday, March 20, 2024
Global leader in Biopharma R&D chooses the Genedata Biopharma Platform to accelerate discovery timelines for protein-based modalities
BASEL, Switzerland, March 12, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, announced today that Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan, has adopted Genedata Biologics® to automate its discovery workflows. The system integrates and automates complex biologics research processes resulting in a significant reduction in discovery timelines. By providing structured, high-quality, and comparable data, Genedata Biologics enables data-driven decisions to select the most promising lead candidates.
"We are very pleased that Daiichi Sankyo has chosen Genedata Biologics to digitalize and automate their novel biologics research operations," said Othmar Pfannes, Ph.D., CEO of Genedata. "The implementation of the Genedata platform by yet another leading Japanese pharmaceutical company is a key milestone in our global expansion strategy and further validates the quality of our software. We are committed to continuing to support our Japanese customers with high priority, and to invest into further developing the Genedata Biopharma Platform for our customers in Japan and around the world to bring novel drugs to patients more quickly."
We are committed to continuing to support our Japanese customers with high priority, and to invest into further developing the Genedata Biopharma Platform for our customers in Japan and around the world to bring novel drugs to patients more quickly. Othmar Pfannes, Ph.D., CEO at GenedataAbout Genedata Biologics
Genedata Biologics is a purpose-built enterprise software platform to increase the efficiency of biopharma R&D end-to-end. It comes with a built-in registration platform for all biological modalities and works out-of-the-box, integrating complex and interconnected workflows from different research groups, and supporting work in division-of-labor environments. The system automates and integrates a broad range of R&D processes such as screening, molecular biology, engineering and optimization, expression and purification, conjugation, and associated analytics. Genedata Biologics structured data model enables an integrative approach to AI/ML in biopharma R&D, such as improving the design of multi-specific molecules in silico, identifying optimal formulation conditions, or better predictions of developability and manufacturability profiles of novel drug candidates.
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn| Twitter| YouTube
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
View original content to download multimedia:https://www.prweb.com/releases/daiichi-sankyo-adopts-genedata-biologics-to-automate-the-discovery-of-novel-biological-therapeutics-302085059.html
SOURCE Genedata
|
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Buyers Edge Platform Appoints Jaime Selga to Lead Expansion Across the Middle East, Africa & Asia | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
|
